Reckitt Benckiser Buys Back Remaining Rights to Suboxone & Subutex

Reckitt Benckiser Buys Back Remaining Rights to Suboxone & Subutex
Reckitt Benckiser Group plc (RB) today announces that it is buying back the sales and marketing rights to the buprenorphine-containing products Suboxone®, Subutex® and Temgesic®* from Merck & Co., Inc.** for approximately £100 million. The rights apply to a number of countries in Europe and the rest of the world, and were due to revert to RB mid-2012. With this acquisition the majority will now revert two years earlier, starting 1 July 2010. The incremental net revenue to RB associated with these rights would have been approximately £80 million for full year 2009, if RB had owned them.

RB currently has management control of the sales and marketing of these products in only two sizeable markets, namely the US and Australia. With this purchase, RB will have a wholly-owned international franchise for Suboxone and Subutex.

RB and Merck's MSD will work closely to ensure a smooth transition in the best interests of patients and healthcare professionals. RB aims to retain as many as possible of the dedicated commercial staff involved in the business, in conformity with applicable local laws. The company will also be investing in additional sales and marketing capability.

Given the current scale of the business outside of the US and the investment needed, the impact of this transaction on RB's financial results in 2010 will be limited.


Notes:
* Suboxone® and Subutex® are opioid dependence treatments and Temgesic® is an analgesic.
** (through an affiliate, "MSD"). Merck & Co., Inc. was previously known as Schering-Plough Corporation

For further information, please contact:
Reckitt Benckiser 
Joanna Speed                                        Investor Relations         +44 (0)1753 217800
Andraea Dawson-Shepherd                Media

Brunswick (Financial PR) 
Susan Gilchrist                                                                                +44 (0)20 7404 5959
David Litterick 

Merck 
Joe Romanelli                                     Investor Relations             +1 908 423 5088
Carol Ferguson                                   Investor Relations             +1 908  423 4465
Monique Mols                                      Media                                   +31 (0) 412 66 5440

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.